Product: **Epinephrine Injection, USP** Revision: 1



AMERICAN REGENT, INC.

MATERIAL SAFETY DATA SHEET

International: +1 703-527-3887

Section 1: PRODUCT AND COMPANY INFORMATION

Luitpold Pharmaceuticals, Inc. Chemtrec 24/7 Emergency Telephone Number P.O. Box 9001 Domestic North America: (800) 424-9300

Shirley, New York 11967

(800) 645-1706 (631) 924-4000

PRODUCT NAME: Epinephrine Injection, USP

PRODUCT CODE (NDC):

1 mg/mL: 0517-1071-25 preservative free/sulfite free

1 mg/mL: 0517-1130-05

Section 2: HAZARDS IDENTIFICATION		
EMERGENCY OVERVIEW		
Appearance / Odor WARNING!	Clear, odorless liquid. (A Chlorobutanol odor is detected in the preserved product.)	
Skin, eye and respiratory irritant	Causes slight irritation of the eyes, skin and respiratory tract.	
Toxicity to fish/aquatic organisms	Product is not known to be toxic to fish.	
Potential Health Effects: See Section 11 for more information		
Likely Routes of Exposure Eye Skin Inhalation Ingestion Skin Absorption Medical Conditions Aggravated by Exposure	Eye contact, skin contact, inhalation and ingestion. Causes irritation of the eye. Causes irritation of the skin. May cause irritation of the upper and lower respiratory tract. May cause irritation of the gastrointestinal tract. Absorbed through the skin. Personnel with sensitivity to this product. Workers with cardiovascular and pulmonary disorders, hypertension, diabetes,	
Target Organs	and hyperthyroidism should minimize their exposure to this product. It is strongly recommended that pregnant workers not be exposed to this product. Cardiovascular, pulmonary and endocrine systems. continued on next page	

Product: **Epinephrine Injection, USP** Revision: 1

Section 2: HAZARDS IDENTIFICATION (continued)

Potential Environmental Effects: This product is not known to be toxic to fish.

See Section 12 for more information

This product does not contain any carcinogens or potential carcinogens as listed by OSHA, IARC or NTP.

This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

Section 3: COMPOSITION AND INFORMATION ON INGREDIENTS		
Component	CAS Number	Percentage (%) by Weight
Epinephrine	51-43-4	0.1 percent
Sodium Chloride	7647-14-5	0.9 percent
Sodium Hydroxide	1310-73-2	used for pH adjustment
Hydrochloric Acid	7647-01-0	used for pH adjustment
Water for Injection	7732-18-5	98.3 to 99.0 percent
Sodium Metabisulfite	7681-57-4	0.2 percent (preserved product only)
Chlorobutanol	57-15-8	0.5 percent (preserved product only)

Section 4: FIRST AID MEASURES		
Eye Contact	Causes irritation. Flush for 15 minutes with copious quantities	
	of water. Seek medical attention.	
Skin Contact	May cause irritation. Remove contaminated clothing. Flush area with copious quantities of water for 15 minutes. Seek medical attention.	
Inhalation	May cause irritation of respiratory tract. Remove person to fresh air. Remove contaminated clothing. Seek medical attention.	
Ingestion	May cause irritation of the gastrointestinal tract. Flush mouth out with water. Seek medical attention.	
Injection	See prescribing information.	
Note to Physicians	Exposure to this product may result in headache, pulmonary edema, tachycardia, palpitations and hypertension.	

Product: **Epinephrine Injection, USP** Revision: 1

Section 5: FIRE FIGHTING MEASURES		
Suitable Extinguishing Media	Water spray, foam, dry chemical or Carbon Dioxide (CO ₂).	
	Caution : CO ₂ will displace air in confined spaces and may	
	cause an Oxygen deficient atmosphere.	
Unsuitable Extinguishing Media	None.	
Hazardous Combustion Products	When heated, Epinephrine solution thermally decomposes to	
	form toxic vapors. (i.e. Carbon Monoxide, Carbon Dioxide and	
	Nitrogen Oxides).	
Protection for Firefighters: Epinephrine solution thermally decomposes to form toxic vapors. Vapors		

<u>Protection for Firefighters</u>: Epinephrine solution thermally decomposes to form toxic vapors. Vapors may be irritating to eyes and skin and toxic to respiratory tract. Firefighters are to wear self-contained breathing apparatus (SCBA) and full turn out gear (Bunker gear). Cool containers with water spray and use caution when approaching.

Section 6: ACCIDENTAL RELEASE MEASURES		
Personnel Precautions	Use personal protective equipment recommended in Section 8 of this document and isolate the hazard area.	
Environmental Precautions	This material is not considered a water pollutant. However, it is recommended to prevent spilled or leaking material from entering waterways. Minimize use of water to prevent environmental contamination.	
Methods of Containment	Absorb material with suitable materials such as clay absorbent or absorbent pads for aqueous solutions.	
Methods of Clean Up	Vacuum spillage with a vacuum cleaner having a high efficiency particulate (HEPA) filter, or absorb liquid with clay absorbent, absorbent pads or paper towels. Use plastic tools to scoop up, sweep or containerize spilled material. Use plastic drums to contain spilled materials. Wipe working surfaces to dryness, and then wash with soap and water.	
Other Information	A spill of this material does not need to be reported to the National Response Center.	

Section 7: HANDLING AND STORAGE

Handling:

As a general rule, when handling pharmaceutical products, avoid all contact and inhalation of mists or vapors associated with the product. Avoid contact with skin, eyes or clothing. Do not mix with other drugs.

Use in a well ventilated area. Wash thoroughly after handling.

Storage:

Protect from light. Store in a well ventilated area. Keep containers closed when not in use. Product residue may remain in empty containers. Observe all label precautions until container is cleaned, discarded or destroyed.

Product: **Epinephrine Injection, USP** Revision: 1

Section 8: EXPOSURE CONTROLS / PERSONAL PROTECTION				
Exposure Guidelines	OSHA PEL		ACGIH TLV	OTHER
Epinephrine	Not lis	ted	Not listed	
Sodium Chloride	Not lis	ted	Not listed	
Water for Injection	Not lis	ted	Not listed	
Chlorobutanol	Not lis	ted	Not listed	
Sodium Metabisulfite	Not lis	ted	5 milligrams per cubic	
			meter	
Hydrochloric Acid	5 parts	per million -	2 parts per million -	
	Ceiling		Ceiling	
Sodium Hydroxide		grams / cubic	2 milligrams / cubic	
	meter -	8 hour TWA	meter - Ceiling	
Personal Protective Equip	nent		Description	
Ven	tilation	Local exhaust	or general ventilation is rec	commended.
Respiratory Protection		Under normal conditions of product use, respiratory protection is not required. When required, use a NIOSH approved air purifying respirator with combination P-100 / organic vapor cartridges.		
Eye Protection		Wear ANSI approved chemical splash goggles or safety glasses.		
Skin Protection		gloves. Use 7	tering this product to patiently yek TM SL or equivalent yes for clean up activities.	

Section 9: PHYSICAL AND CHEM	IICAL PROPERTIES	
Color	Clear, colorless solution	
Odor / Odor Threshold	Odorless (A Chlorobutanol odor is detected in the preserved	
	product.)	
Physical State	Liquid	
рН	2.2 to 5.0	
Freezing Point	Approximately 32 degrees Fahrenheit	
Boiling Point	Approximately 212 degrees Fahrenheit	
Flash Point	Not applicable	
Evaporation Rate	Not applicable	
Flammability	Nonflammable, noncombustible	
Upper Flammable Limit	Not applicable	
Lower Flammable Limit	Not applicable	
Vapor Pressure	Not applicable	
Vapor Density	Not applicable	
Specific Gravity	Approximately 1.0	
Solubility (water)	Freely soluble in water	
Partition Coefficient	Not applicable	
Auto-ignition Temperature	Not applicable	
Percent Volatile	0 Percent	
Volatile Organic Compounds (%)	0 Percent	

Product: **Epinephrine Injection, USP** Revision: 1

Section 10: STABILITY AND REACTIVITY		
Stability	Stable.	
Conditions to Avoid	Do not mix with other drugs. Avoid heat, light and humidity. Keep away from flames, thermally decomposes to form toxic vapors.	
Incompatible Materials	Reactive with oxidizers.	
Hazardous Decomposition Products	Carbon Monoxide, Carbon Dioxide and Nitrogen Oxides may be released by thermal decomposition.	
Possibility of Hazardous Reaction	Hazardous polymerization will not occur.	

Section 11: TOXICOLOGY INFORMATION		
Acute Effects		
Oral (LDLo)	LDLo:	50 mg/kg oral - mouse
Subcutaneous (LD ₅₀)	LD ₅₀ :	1.47 mg/kg subcutaneous - mouse
Letoman and A.D.	ID.	0.15 / :
Intravenous (LD ₅₀)	LD ₅₀ :	0.15 mg/kg intravenous- rat
	LD ₅₀ :	0.217 mg/kg intravenous - mouse
Intramuscular (LD ₅₀)	LD ₅₀ :	3500 mg/kg intramuscular- rat
muamusculai (LD50)	LD ₅₀ .	5500 mg/kg milamuscular- lat
Intraperitoneal (LD ₅₀)	LD ₅₀ :	4 mg/kg intraperitoneal - mouse
300	30*	8 8 11
Dermal (LD ₅₀)	LD ₅₀ :	62 mg/kg dermal - rat
Inhalation	Respiratory irritation is possible.	
Eye Irritation	Eye irritation is possible.	
Skin Irritation	Skin irritation is possible.	
Skiii IIIItation	Skill illitation is possible.	
Sensitization	Some personnel may have sensitivity to this product. Sodium	
	Metabisulfite may cause an anaphylactic reaction in exposed	
	workers.	
		continued on next page

Product: **Epinephrine Injection, USP** Revision: 1

Section 11: TOXICOLOGY INFORMATION (continued)		
Chronic Effects		
Organ Systems	Prolonged or repeated exposure may lead to accumulation and damage to cardiovascular and pulmonary systems.	
Carcinogenicity	Epinephrine is not considered carcinogenic. No adequate and well controlled studies in humans have been conducted.	
Mutagenicity	One animal cell study classified epinephrine as mutagenic. No adequate and well controlled studies in humans regarding the mutagenic effects of Epinephrine. Sodium Chloride is considered mutagenic for mammalian somatic cells, bacteria and yeast.	
Reproductive Effects	Animal studies have demonstrated that Epinephrine is embryotoxic. No adequate and well controlled studies in humans have been conducted.	
Developmental Effects	Above prescribed doses, Epinephrine was found to be teratogenic in animal studies. No adequate and well controlled studies in humans. Classified as Pregnancy Category C.	

Section 12: ECOLOGICAL INFORMATION		
Ecotoxicity	No data available.	
Persistence / Degradability	Short term products of biodegradation are not likely. Long term degradation products may arise.	
Bioaccumulation / Accumulation	No applicable bioaccumulation is expected in the environment.	
Mobility in Environment	Appreciable volatilization is not expected into the air.	

Section 13: DISPOSAL CONDITIONS		
Disposal	Do not mix with other substances. Dispose of in accordance	
	with Federal, state and local regulations. Contact your state or	
	local government environmental and / or sanitation department	
	for guidance on disposal.	

Section 14: TRANSPORTATION INFORMATION	
Regulatory Agency	Shipping Description.
US DOT (ground)	Not considered a DOT regulated material - Non hazardous for shipment.
Canadian TDG (ground)	See US DOT
IATA (air)	Not considered a DOT regulated material - Non hazardous for shipment.

Product: **Epinephrine Injection, USP** Revision: 1

Section 15: REGULATORY INFORMATION	
STATE RIGHT TO KNOW	Refer to the applicable state to determine applicability.
California Safe Drinking Water & Toxic Enforcement Act (Prop 65)	This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins under California Proposition 65.
RTECS Number	DO2625000
TSCA	8b Inventory - Epinephrine
SARA 313	Notify and report release if above threshold quantity (1000 pounds).
NFPA Rating	Health - 2, Fire - 1, Reactivity - 0
WHMIS (Canada)	D-1A - Causes immediate and serious toxic effects D-2B - Causes other toxic effects

Section 16: OTHER INFORMATION

In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock.

Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see prescribing information – Contraindications).

Refer to Luitpold / American Regent's prescribing information for further information at http://www.americanregent.com/product_index.asp

Prepared By: Christopher Seniuk CIH CSP

The information above is believed to be accurate and represents the best information currently available to American Regent. The information has not been verified and we cannot, therefore, guarantee its accuracy or completeness or adequacy for all persons and situations or as to the results to be obtained by use of the information. It is the user's obligation to evaluate and use this product safely and to comply with all applicable laws and regulations. WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, WITH RESPECT TO SUCH INFORMATION AND WE ASSUME NO LIABILITY RESULTING FROM ITS USE. Users should make their own investigations to determine the suitability of the information for their own particular purposes. The user assumes all risks from use of the product. In no event shall Luitpold, its subsidiaries, its affiliates and its contractors be liable for any claims, losses or damages of any third

Product: **Epinephrine Injection, USP** Revision: 1

party, or for lost profits, or for any special, indirect, incidental, consequential or exemplary damages however arising, even if Luitpold has been advised of the possibility of such damages.